A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared With Gurabo Risperdal Tablets

Trial Profile

A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared With Gurabo Risperdal Tablets

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Risperidone (Primary)
  • Indications Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Xian-Janssen
  • Most Recent Events

    • 27 Feb 2018 Planned primary completion date changed from 27 Apr 2018 to 2 Jan 2018.
    • 27 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.
    • 21 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top